Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D04NPP
|
||||
Former ID |
DNCL001638
|
||||
Drug Name |
SLX-2101
|
||||
Indication | Erectile dysfunction; Hypertension; Raynaud's disease [ICD9: 302.72, 607.84, 401, 443; ICD10:F52.2, N48.4, I10-I16, I73.0] | Discontinued in Phase 2 | [548157] | ||
Company |
Kadmon Pharmaceuticals; Nano Terra
|
||||
Target and Pathway | |||||
Target(s) | CGMP-specific 3',5'-cyclic phosphodiesterase | Target Info | Inhibitor | [529481] | |
KEGG Pathway | Purine metabolism | ||||
cGMP-PKG signaling pathway | |||||
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
Reactome | cGMP effects | ||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.